

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 2ND BOARD MEETING FOR FY2025

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 14 April 2025, the Company duly convened its 2nd Board meeting for the financial year ending 31 December 2025 (“**FY2025**”) through a combination of a physical meeting and teleconference. The said meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The full Board of nine (9) Directors were present, and the following resolutions were duly passed:

1. That the proposed disposal of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) (the “**Target Company**”), and the proposed entry into an equity transfer agreement in relation thereto, be approved.

The Company proposes to transfer its 4.6% and 7.4% equity interests in the Target Company to Haleon China Co., Ltd. (赫力昂 (中国) 有限公司) and Haleon CH SARL, respectively, for a consideration of RMB622,328,888.89 and RMB1,001,137,777.78 (the “**Proposed DRT Disposal**”). Upon completion of the Proposed DRT Disposal, the Company will cease to hold any equity interest in the Target Company.

Please refer to the Company’s announcement titled “*Proposed Disposal of the Remaining 12% Equity Interest in Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) to Haleon China Co., Ltd. and Haleon CH SARL, and Entry into an Equity Transfer Agreement in relation thereto*” released on the same date as this announcement for further information.

2. That, pursuant to the applicable Company Law and the Articles of Association of the Company, the proposed convening of the 1st extraordinary general meeting of the Company in 2025 (the “**2025 1st EGM**”) be approved.

The resolution referred to in paragraph 1 above will be tabled for shareholders’ approval at the 2025 1st EGM, notice of which will be issued in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
15 April 2025